ELI LILLY AND COMPANY Other Current Assets
ELI LILLY AND COMPANY (LLY) had Other Current Assets of $86.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:OtherAssetsCurrent · last filed 2026-08-05
- 2026-06-30: Other Assets, Current $86.00M.
- 2026-03-31: Other Assets, Current $214.00M.
- 2025-12-31: Other Assets, Current $147.00M.
- 2025-09-30: Other Assets, Current $271.50M.
| Period end | Other Assets, Current | Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $86.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $214.00M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $147.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $271.50M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $68.80M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $72.40M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $266.00M 10-K · filed 2026-02-12 | $111.40M 10-K · filed 2025-02-19 |
| 2024-09-30 | $134.60M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $142.20M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $138.60M 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $149.50M 10-K · filed 2025-02-19 | |
| 2022-12-31 | $7.30M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |